Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment

Volumn 17, Issue 29, 2013, Pages 1-385

  Ford, J ^a   Cummins, E ^b   Sharma, P ^a   Elders, A ^a   Stewart, F ^a   Johnston, R ^b   Royle, P ^c   Jones, R ^d   Mulatero, C ^e   Todd, R ^f   Mowatt, G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b McMDC Ltd   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; STRONTIUM CHLORIDE; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE INJURY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHILL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG FEVER; DRUG INDICATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG USE; DRUG WITHDRAWAL; ESOPHAGITIS; FLU LIKE SYNDROME; FLUSHING; FUNCTIONAL ASSESSMENT; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; LIVER CANCER; LUNG NON SMALL CELL CANCER; MEDICAL HISTORY; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN INFECTION; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MODELS, ECONOMIC; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84881078296     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17290     Document Type: Article

References (213)

1. Office for National Statistics. Statistical bulletin: births and deaths in England and Wales. Newport: Office for National Statistics; 2009. URL: www. ons.gov.uk/ons/publications/index.html (accessed October 2011).
2. Cancer Research UK. Latest UK cancer incidence (2008) and mortality (2008) summary. London: Cancer Research UK; 2011. URL: http://info.cancerresearchuk.org/prod_consump/groups/ cr_common/@nre/@sta/documents/generalcontent/cr_072108.pdf (accessed October 2011).
3. Jensen AT, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 2011;11;29.
4. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:S1588-94.
5. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40. http://dx.doi.org/10.1038/bjc.1998.52
6. National Institute for Health and Care Excellence (NICE). TA101: docetaxel for the treatment of hormone-refractory metastatic prostate cancer. London: NICE; 2006. URL: www. nice.org.uk/ nicemedia/live/11578/33348/33348.pdf (accessed October 2011).
7. Bubendorf L, Schapfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000;31:578-83. http://dx.doi. org/10.1053/hp.2000.6698
8. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010;184:162-7. http://dx.doi.org/10.1016/j.juro.2010.03.034
9. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level pp4.0 ng per milliliter. N Engl J Med 2004;350:2239-46. http://dx.doi.org/10.1056/NEJMoa031918
10. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. http://dx.doi. org/10.1056/NEJMoa1014618
11. Cancer Research UK. Cancer survival statistics by cancer site. London: Cancer Research UK; 2009. URL: http://info.cancerresearchuk.org/cancerstats/survival/siteandsex/ (accessed October 2011).
12. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76. http://dx.doi.org/10.1053/ctrv.2000.0210
13. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:S6243-9. http://dx.doi.org/10.1158/1078-0432.CCR-06-0931
14. Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum 1999;42:1592-7. http://dx.doi.org/10.1007/BF02236213
15. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005;5:108-13. http://dx.doi. org/10.3816/CCC.2005.n.022
16. McCawley LJ, Matrisian LM. Tumor progression: defining the soil round the tumor seed. Curr Biol 2001;11:R25-7. http://dx.doi.org/10.1016/S0960-9822(00)00038-5
17. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64. http://dx.doi. org/10.1056/NEJMra030831
18. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93. http://dx.doi.org/10.1038/nrc867
19. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7. http://dx.doi. org/10.1002/cncr.22991
20. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 2010;123:767-79. http:// dx.doi.org/10.1007/s10549-010-0981-1
21. Koizumi M, Yoshimoto M, Kasumi F, Iwase T, Ogata E. Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer 2010;10:423. http://dx.doi. org/10.1186/1471-2407-10-423
22. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol
23. Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91. http://dx.doi.org/10.1056/ NEJM199612123352401
24. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14:177-83. http://dx.doi.org/10.1038/pcan.2011.7
25. Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 2011;129:495-503. http://dx.doi.org/10.1007/ s10549-011-1475-5
26. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009;10:606-14. http://dx.doi.org/10.1016/S1470-2045(09)70088-9
27. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14:6690-6. http://dx.doi.org/10.1158/1078-0432. CCR-07-5234
28. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-7. http://dx.doi. org/10.1038/sj.bjc.6601437
29. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeketal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69. http://dx.doi.org/10.1093/jnci/dji002
30. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22. http://dx.doi.org/10.1016/S0140-6736(10)62344-6
31. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32. http://dx.doi.org/10.1200/JCO.2010.31.3304 c31.
32. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9. http://dx.doi.org/10.1200/ JCO.2010.29.7101
33. Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35. http://dx.doi.org/10.1200/ JCO.2005.06.091
34. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035-43. http://dx.doi.org/10.1634/theoncologist.12-9-1035
35. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-7. http://dx.doi. org/10.1200/JCO.2010.32.5209
36. Falicov A, Fisher CG, Sparkes J, Boyd MC, Wing PC, Dvorak MF. Impact of surgical intervention on quality of life in patients with spinal metastases. Spine 2006;31:2849-56. http://dx.doi. org/10.1097/01.brs.0000245838.37817.40
37. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-76. http://dx.doi.org/10.1016/j.ijrobp.2010.11.026
38. Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 2010;18:197-203. http://dx.doi.org/10.1007/s00520-009-0645-z
39. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20. http://dx.doi.org/10.1214/aos/1176345976
40. Major PP, Cook RJ. Clinical endpoints for assessing bisphosphonate efficacy in the prevention of skeletal complications of bone metastases. Eur Urol Suppl 2004;3:34-9. http://dx.doi.org/10.1016/j. eursup.2004.08.010
41. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000;56:554-62. http://dx.doi.org/10.1111/j.0006-341X.2000.00554.x
42. Cook RJ, Lawless JF. Marginal analysis of recurrent events and a terminating event. Stat Med 1997;16:911-24. http://dx.doi.org/10.1002/(SICI)1097-0258(19970430)16:8/911::AID-SIM54493.0.CO;2-I
43. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001;93:534-8. http://dx.doi.org/10.1093/jnci/93.7.534
44. Clemons M, Dranitsaris G, Cole D, Gainford MC. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 2006;11:227-33. http://dx.doi.org/10.1634/theoncologist.11-3-227
45. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19:755-60. http://dx.doi. org/10.1111/j.1365-2354.2009.01135.x
46. National Institute for Health and Care Excellence (NICE). CG81: Advanced breast cancer: diagnosis and treatment. London: NICE; 2009. URL: www. nice.org.uk/nicemedia/live/11778/43414/43414.pdf (accessed October 2011).
47. National Institute for Health and Care Excellence (NICE). CG58: Prostate cancer: diagnosis and treatment. London: NICE; 2008. URL: www. nice.org.uk/nicemedia/live/11924/39687/39687.pdf (accessed October 2011).
48. National Institute for Health and Care Excellence (NICE). CG75: Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. London: NICE; 2008. URL: www. nice.org.uk/nicemedia/live/12085/42668/42668.pdf (accessed October 2011).
49. National Institute for Health and Care Excellence (NICE). CG121: The diagnosis and treatment of lung cancer (update). London: NICE; 2011. URL: www. nice.org.uk/nicemedia/ live/13465/54199/54199.pdf (accessed October 2011).
50. National Institute for Health and Care Excellence (NICE). CG121: The diagnosis and treatment of lung cancer (update). London: NICE; 2011. p. 105. URL: www. nice.org.uk/nicemedia/ live/13465/54199/54199.pdf (accessed October 2011).
51. National Institute for Health and Care Excellence (NICE). CG121: The diagnosis and treatment of lung cancer-Appendix 10. London: NICE; 2011. p. 22. URL: www. nice.org.uk/nicemedia/ live/13465/54206/54206.pdf (accessed October 2011).
52. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 106: Control of pain in adults with cancer. Edinburgh: SIGN; 2008. URL: www. sign.ac.uk/pdf/SIGN106.pdf (accessed October 2011).
53. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 84: Management of breast cancer in women. Edinburgh: SIGN; 2005. URL: www. sign.ac.uk/pdf/sign84.pdf (accessed October 2011).
54. De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009;4:1280-8. http://dx.doi.org/10.1097/JTO.0b013e3181b68e5a
55. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-45. http://dx.doi.org/10.4065/83.9.1032
56. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004;8(4).
57. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-2. http://dx.doi. org/10.1007/BF01622190
58. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-36. http://dx.doi.org/10.1177/009127002762491316
59. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341. http://dx.doi.org/10.1136/bmj.c4444
60. Fallowfield L, Stebbing J, Braybrooke J, Langridge C, Jenkins V. The preferences and experiences of different bisphosphonate treatments in women with breast cancer. Psychooncology 2011;20:755-61. http://dx.doi.org/10.1002/pon.1781
61. Chern B, Joseph D, Joshua D, Pittman K, Richardson G, Schou M, et al. Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 2004;12:463-6. http://dx.doi. org/10.1007/s00520-004-0628-z
62. McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model. J Support Oncol 2006;4:524-9.
63. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. http://dx.doi.org/10.1200/JCO.2005.02.8670
64. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2010;5:CD007309.
65. Fallowfield L, Jenkins V, Coleman R. Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. Breast 2008;17:459-63. http:// dx.doi.org/10.1016/j.breast.2008.02.009
66. Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K. Estimating minimally important differences for the worst pain rating of the brief pain inventory-short form. J Support Oncol 2011;9:72-8. http://dx.doi.org/10.1016/j.snoc.2010.12.004
67. National Institute for Health and Care Excellence (NICE). CG121 Appendix 10. London: NICE; 2011. p.147. URL: www. nice.org.uk/nicemedia/live/13465/54206/54206.pdf (accessed October 2011).
68. Higgins JPT, Altman DG, Sterne JAC, Cochrane Statistical Methods Group, Cochrane Bias Methods Group. Assessing risk of bias in included studies. In Cochrane Handbook for Systematic reviews of Interventions. The Cochrane Collaboration; 2011. URL: www. cochrane-handbook.org (accessed August 2011).
69. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. http://dx.doi.org/10.1002/sim.1875
70. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield: NICE Decision Support Unit; 2011. URL: www. nicedsu.org.uk/TSD2%20General%20 meta%20analysis%20corrected%20Mar2013.pdf (accessed August 2011).
71. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. http://dx.doi.org/10.1186/1745-6215-8-16
72. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405. http://dx.doi.org/10.1093/annonc/mdg367
73. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-12. http://dx.doi.org/10.1016/j.pain.2004.07.011
74. Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, et al. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 1988;42:111-16.
75. Heras P, Kritikos K, Hatzopoulos A, Georgopoulou AP. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care (Engl) 2009;18:653-6. http://dx.doi.org/10.1111/j.1365-2354.2008.00980.x
76. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74. http:// dx.doi.org/10.1046/j.1365-2796.1999.00507.x
77. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
78. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 1989;116:67-72. http://dx.doi. org/10.1007/978-3-642-83668-8_6
79. Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14:349-51. http://dx.doi.org/10.1007/BF00254382
80. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-11. http://dx.doi.org/10.1093/jnci/djg038
81. Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol 1992;24:159-66. http://dx.doi.org/10.1007/BF02549644
82. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/ prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-42. http://dx.doi.org/10.1200/JCO.2003.03.042
83. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993;29A:821-5.
84. Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I. Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997;76:939-42. http://dx.doi.org/10.1038/bjc.1997.488
85. Nilsson S, Strang P, Ginman C, Zimmermann R, Edgren M, Nordstrom B, et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage 2005;29:352-7. http://dx.doi.org/10.1016/j.jpainsymman.2004.07.008
86. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13. http://dx.doi.org/10.1016/0360-3016(93)90309-J
87. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40. http://dx.doi.org/10.1016/0167-8140(94)90411-1
88. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84. http://dx.doi.org/10.1200/ JCO.2003.05.147
89. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-7.
90. Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst E, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997;17:4717-21.
91. Arican A, Icli F, Akbulut H, Cakir M, Sencan O, Samur M, et al. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Med Oncol 1999;16:204-10. http:// dx.doi.org/10.1007/BF02906133
92. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200. http:// dx.doi.org/10.1002/1097-0142(20010401)91:7/1191::AID-CNCR111913.0.CO;2-0
93. Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, et al. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 2007;81:341-51. http://dx.doi.org/10.1007/s00223-007-9061-x
94. Heras Rincon, I, Zubillaga RI, Castrillo Tambay M, Montalvo Moreno JJ. [Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations.] Med Oral Patol Oral Cir Bucal 2007;12:E267-71.
95. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-8. http://dx.doi.org/10.1023/A:1012506426440
96. Mystakidou K, Stathopoulou E, Parpa E, Kouloulias V, Kouskouni E, Vlahos L. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J Cancer Res Clin Oncol 2008;134:1303-10. http://dx.doi.org/10.1007/s00432-008-0419-x
97. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995;13:929-34.
98. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998;17:213-17.
99. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a doubleblind, placebo-controlled study. J Clin Oncol 1995;13:2427-30.
100. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010;15:382-9. http://dx.doi.org/10.1007/s10147-010-0074-5
101. Zhao YY, Xue C, Hou X, Liao H, Li S, Zhao HY, et al. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. Eur J Cancer 2011;47:848-53. http://dx.doi.org/10.1016/j.ejca.2010.12.004
102. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-9. http://dx.doi.org/10.1002/cncr.11571
103. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21. http://dx.doi. org/10.1200/JCO.2005.05.116
104. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90. http://dx.doi.org/10.1002/ (SICI)1097-0142(20000301)88:5(1082::AID-CNCR2013.0.CO;2-Z
105. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44. http://dx.doi.org/10.1002/cncr.11701
106. Fallowfield L, Patrick D, Body J, Lipton A, Tonkin KS, Qian Y, et al. Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: results from a randomized phase III trial. J Clin Oncol 2010;28(Suppl. 27):1025.
107. Fallowfield L, Patrick D, Body JJ, Lipton A, Tonkin KS, Qian Y, et al. The effect of treatment with denosumab or zoledronic acid on health-related quality of life in patients with metastatic breast cancer. Cancer Res 2010;70(Suppl. 2):P1-13-05.
108. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
109. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
110. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43. http://dx.doi.org/10.1002/cncr.11892
111. Stopeck A, Fallowfield L, Patrick D, Cleeland CS, de Boer RH, Steger GG, et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: results from a phase III clinical trial. J Clin Oncol 2010;28(Suppl. 15):1024.
112. Stopeck A, Fallowfield L, Patrick D, Cleeland CS, de Boer RH, Steger GG, et al. Pain in patients (pts) with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid (ZA). 33rd Annual San Antiono Breast Cancer Symposium 8-12 December 2010. URL: http://www. asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=100&abstractID=60225 (accessed September 2011).
113. Stopeck A, Martin M, Ritchie D, Body JJ, Paterson A, Viniegra M, et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: Results from the extended blinded treatment phase. Cancer Res 2010;70(Suppl. 2):P6-14-01.
114. Stopeck A, Lipton AA, Campbell-Baird C, von Moos R, Fan M, Haddock B, et al. Acute-phase reactions following treatment with zoledronic acid or denosumab: Results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Res 2010;70(Suppl. 2):P6-14-09.
115. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Reply to V. Fusco et al. J Clin Oncol 2011;29:e523-4. http://dx.doi.org/10.1200/JCO.2011.35.2203
116. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
117. Martin M, Steger G, von Moos R, Stopeck A, de Boer R, Bourgeois H, et al. Benefit of denosumab therapy in patients with bone metastases from breast cancer: a number-needed-to-treat (NNT) analysis. Breast 2011;20:S85. http://dx.doi.org/10.1016/S0960-9776(11)70283-1
118. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68. http://dx.doi.org/10.1093/jnci/94.19.1458
119. Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urol 2010;76:1175-81. http://dx.doi.org/10.1016/j. urology.2010.05.026
120. Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390-6. http:// dx.doi.org/10.3816/CGC.2007.n.022
121. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005;4:31-7. http://dx.doi.org/10.3816/CGC.2005.n.009
122. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004;96:879-82. http://dx.doi.org/10.1093/jnci/ djh141
123. Brown JE, Cleeland CS, Fallowfield LJ, Patrick DL, Fizazi K, Smith MR, et al. Pain outcomes in patients with bone metastases from castrate-resistant prostate cancer: results from a phase 3 trial of denosumab vs. zoledronic acid. Eur Urol Suppl 2011;10:336. http://dx.doi.org/10.1016/ S1569-9056(11)61070-1
124. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 2004;46:731-9. http://dx.doi. org/10.1016/j.eururo.2004.08.016
125. Miller K, Fizazi K, Smith M, Moroto JP, Klotz L, Brown J, et al. Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: a number-needed-to-treat (NNT) analysis. J Urol 2011;185(Suppl. 1):e262. http://dx.doi.org/10.1016/j.juro.2011.02.1550
126. Patrick D, Cleeland C, Fallowfield L, Smith MR, Trachtenberg J, Chilingirov P, et al. Effects of denosumab and zoledronic acid on pain interference with daily functioning in patients with castrate-resistant prostate cancer. J Urol 2011;185(Suppl. 1):e286. http://dx.doi.org/10.1016/j. juro.2011.02.1679
127. European Medicines Agency. Assessment report for zometa (zoledronic acid). London: European Medicines Agency; 2010. URL: www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000336/human_med_001182.jsp&mid=WC0b01ac058001d124# (accessed October 2011).
128. Tadros S. Clinical Study Report: 20050103. A randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in men with hormone-refractory prostate. Thousand Oaks, CA: Amgen Inc.; 2010.
129. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 2006;17:986-9. http:// dx.doi.org/10.1093/annonc/mdl041
130. Shore ND, Smith MR, Jievaltas M, Fizazi K, Damiao R, Chin J, et al. Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: subgroup analyses by prior SRE and baseline pain. J Clin Oncol 2011;29(Suppl.):4533.
131. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7. http://dx.doi.org/10.1200/ JCO.2003.04.105
132. O'Neill S. Clinical Study Report: 20050244. A randomized, double-Blind, multicenter study of denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in subjects with advanced cancer excluding breast and prostate Cancer) or multiple myeloma. Thousand Oaks, CA: Amgen Inc.; 2010.
133. Henry DH, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, et al. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. J Clin Oncol 2010;15(Suppl.):9133.
134. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21. http://dx.doi.org/10.1002/cncr.20308
135. von Moos R, Patrick D, Fallowfield L, Cleeland CS, Henry DH, Qian Y, et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): results from a randomized phase III clinical trial. J Clin Oncol 2010;28(Suppl.):9043.
136. Schulman CC. Efficacy of zoledronic acid in the treatment of bone metastases secondary to renal cell carcinoma. Eur Urol Suppl 2004;3:40-5. http://dx.doi.org/10.1016/j.eursup.2004.08.011
137. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez M, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-60. http://dx.doi.org/10.1093/annonc/mdl408
138. Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, et al. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol 2010;27:224-9. http://dx.doi.org/10.1007/s12032-009-9195-y
139. Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Int Med J 2008;38:635-7. http://dx.doi. org/10.1111/j.1445-5994.2007.01580.x
140. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 2011;127:429-38. http://dx.doi.org/10.1007/s10549-011-1429-y
141. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704-12. http://dx.doi.org/10.1016/j. ejca.2004.03.025
142. Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 2009;17:719-25. http://dx.doi.org/10.1007/s00520-008-0553-7
143. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008;13:911-20. http://dx.doi.org/10.1634/theoncologist.2008-0091
144. Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, et al. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dental Assoc 2011;142:506-13.
145. Garcia Saenz JA, Lopez TS, Garcia PB, Rodriguez LL, Villalobos L, Diaz RE. [Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.] Med Oral Patol Oral Cir Bucal 2007;12:E351-6.
146. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005;10:842-8. http://dx.doi.org/10.1634/theoncologist.10-10-842
147. Haidar A, Jonler M, Folkmar TB, Lund L. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 2009;43:442-4. http://dx.doi.org/10.3109/00365590903295193
148. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Mineral Res 2008;23:826-36. http://dx.doi.org/10.1359/jbmr.080205
149. Houston S, Grieve RJ, Hickish T, Percival F, Hamilton E. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. J Med Econ 2010;13:162-7. http://dx.doi. org/10.3111/13696991003640383
150. Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist 2008;13:330-6. http://dx.doi.org/10.1634/theoncologist.2007-0159
151. Jackson GH. Renal safety of ibandronate. Oncologist 2005;10:14-18. http://dx.doi.org/10.1634/ theoncologist.10-90001-14
152. La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, et al. Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution. Support Care Cancer 2008;16:1311-15. http://dx.doi.org/10.1007/ s00520-008-0484-3
153. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007;109:1090-6. http://dx.doi.org/10.1002/cncr.22504
154. Pandey R, Dey S, Mukhopadhyay A. The better bisphosphonate in patients with bone metastasis: zoledronic acid or ibandronic acid? A study from Eastern India. J Clin Oncol 2009;27:e20524.
155. Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergstrom B. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315-22. http://dx.doi.org/10.2165/00044011-200626060-00002
156. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45. http://dx.doi.org/10.1093/annonc/mdn526
157. Shah SR, Jean GW, Keisner SV, Gressett Ussery SM, Dowell JE. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Support Care Cancer 2012;20:87-93. http://dx.doi.org/10.1007/s00520-010-1067-7
158. Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonateassociated osteonecrosis of the jaws. Head Neck 2009;31:202-6. http://dx.doi.org/10.1002/ hed.20941
159. Tralongo P, Repetto L, Di MA, Mauceri G, Bollina R, Ferrau' F, et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004;67:112-16. http:// dx.doi.org/10.1159/000080996
160. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62. http://dx.doi.org/10.1200/JCO.2009.21.9584
161. Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72. http://dx.doi.org/10.1016/j. eururo.2008.06.070
162. Zuradelli M, Masci G, Biancofiore G, Gullo G, Scorsetti M, Navarria P, et al. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. Oncologist 2009;14:548-56. http://dx.doi.org/10.1634/theoncologist.2008-0227
163. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized activecontrolled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7. http://dx.doi.org/10.1200/JCO.2007.11.8604
164. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;182:509-15. http://dx.doi. org/10.1016/j.juro.2009.04.023
165. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010;25:440-6. http://dx.doi.org/10.1359/jbmr.090810
166. Carteni G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006;11:841-8. http://dx.doi.org/10.1634/theoncologist.11-7-841
167. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004;15:743-50. http://dx.doi.org/10.1093/annonc/mdh173
168. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit; 2010. URL: www. pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf (accessed October 2011).
169. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-9. http:// dx.doi.org/10.1007/s005200050260
170. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9.
171. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol 2005;28:8-16. http://dx.doi.org/10.1097/01. coc.0000138966.66780.3e
172. De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005;27:1295-310. http://dx.doi.org/10.1016/j.clinthera.2005.08.006
173. De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005;13:975-86. http://dx.doi.org/10.1007/s00520-005-0828-1
174. Guest JF, Clegg JP, Davie AM, McCloskey E. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Curr Med Res Opin 2005;21:805-15. http://dx.doi.org/10.1185/030079905X40472
175. Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82. http://dx.doi.org/10.1093/annonc/mdl093
176. Botteman MF, Stephens J, Foley I, Kaura S. Cost Effectiveness of Zoledronic Acid in the Prevention of Skeletal Related Events in Renal Cell Carcinoma Patients with Bone Metastases: An Exploratory Analysis for France. Eur Urol Suppl 2009;8:157.
177. Botteman MF, Logman JFS, Kaura S. Cost-effectiveness assessment of zoledronic acid (zol) relative to placebo (Pbo) in the treatment of lung cancer patients with skeletal metastases in five European countries. Value Health 2009;12:A271. http://dx.doi.org/10.1016/S1098-3015(10)74329-1
178. Botteman MF, Kaura S. Comparison of the cost-effectiveness of zoledronic acid therapy for renal cell carcinoma (Rcc) patients with bone metastases in French, German, and the UK populations. Value Health 2009;12:A270-1. http://dx.doi.org/10.1016/S1098-3015(10)74325-4
179. Botteman MF, Stephens J, Foley I, Kaura S. Cost effectiveness of zoledronic acid in the prevention of skeletal related events in renal cell carcinoma patients with bone metastases: an exploratory analysis for France. Eur Urol Suppl 2009;8:157. http://dx.doi.org/10.1016/S1569-9056(09)60151-2
180. Botteman MF, Stephens JM, Foley I, Kaura S. Zoledronic acid is cost effective for the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: a French exploratory analysis. J Urol 2009;181:500. http://dx.doi.org/10.1016/S0022-5347(09)61414-2
181. Botteman MF, Kaura S. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: comparison between France, Germany, and the United Kingdom. J Clin Oncol 2009;27:5106.
182. Joshi AD, Carter JA, Botteman MF, Kaura S. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom. Clin Ther 2011;33:291-304. http://dx.doi.org/10.1016/j. clinthera.2011.04.002
183. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001;9:545-51. http://dx.doi.org/10.1007/s005200100249
184. Carter JA, Snedecor SJ, Kaura S, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). J Clin Oncol 2011;29(Suppl.):9025.
185. Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537-42. http://dx.doi.org/10.1097/01.ju.0000116777.94426.60
186. Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011;17:621-43.
187. Tchekmedyian NS, Chen YM, Saad F. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest 2010;28:849-55. http://dx.doi.org/10.3109/07357907.2010.483508
188. Stephens J. Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients (LC pts): comparison across three European countries. J Clin Oncol 2009;27(Suppl. 1):8081.
189. Botteman MF, Kaura S. Assessment of the cost-effectiveness of zoledronic acid in the management of skeletal metastases in lung cancer patients in France, Germany, and the United Kingdom. J Thorac Oncol 2009;4:S542-3.
190. Botteman M, Hay JW, Stephens JM, Barghout V, Quednau K. A Markov model to evaluate the cost effectiveness of five bisphosphonate therapies in the prevention of bone complications in breast cancer patients with bone metastases: a German outpatient perspective. Eur J Cancer Suppl 2005;3:119. http://dx.doi.org/10.1016/S1359-6349(05)80721-9
191. Botteman M, Carter J, Kaura S. A comparison of the cost-effectiveness of zoledronic acid for preventing skeletal-related events in patients with bone metastases from prostate cancer in 4 European countries. Value Health 2010;13:A264. http://dx.doi.org/10.1016/ S1098-3015(11)71966-0
192. El Ouagari K, Botteman M, Aapro M, Hay J, Stephens J, Brandman JP. Cost-effectiveness of zoledronic acid vs. other bisphosphonate agents for the prevention of bone complications in breast cancer: an application to Canada. Eur J Cancer Suppl 2005;3:117. http://dx.doi.org/10.1016/ S1359-6349(05)80716-5
193. Meijboom M, Botteman MF, Kaura S. Cost effectiveness of zoledronic acid for the prevention of skeletal related events in prostate cancer patients with bone metastases in France and Germany. Eur Urol Suppl 2009;8:132. http://dx.doi.org/10.1016/S1569-9056(09)60055-5
194. Snedecor SJ, Carter JA, Kaura S, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC)q. J Clin Oncol 2011;29(Suppl.):4581.
195. Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, et al. Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases. J Clin Oncol 2011;29(Suppl.):e15115.
196. Clohisy DR, Le CT, Cheng EY, Dykes DC, Thompson RC Jr. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. J Orthop Res 2000;18:1-9. http://dx.doi.org/10.1002/jor.1100180102
197. Matza LS, van Brunt K, Chung K, Brazier J, Braun AH, Currie B, et al. Health state utilities for skeletal-related events associated with bone metastases. J Clin Oncol 2011;29(Suppl.):e16620.
198. Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011;16:121-32. http://dx.doi. org/10.1634/theoncologist.2010-0183
199. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003;95:222-9. http://dx.doi.org/10.1093/ jnci/95.3.222
200. Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin 2007;23:1575-82. http:// dx.doi.org/10.1185/030079907X210543
201. Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol 2009;6:494-502. http://dx.doi.org/10.1016/S1548-5315(11)70357-6
202. Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA. Painful bone metastases in hormonerefractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology 1997;50:747-53. http://dx.doi.org/10.1016/S0090-4295(97)00326-9
203. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32. http://dx.doi.org/10.1016/ S0302-2838(03)00007-1
204. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-6. http://dx.doi.org/10.1159/000082923
205. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7.
206. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care 2008;14:317-22.
207. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702.
208. Janus N, Le Tourneau C, Launay-Vacher V, Gligorov J, Rixe O, Pourrat X, et al. Renal insufficiency in bone metastasis cancer patients: prevalence and implications on anticancer drugs management, subgroup analysis of the IRMA study. J Clin Oncol 2007;25(Suppl. 18):9121.
209. Scagliotti G, Hirsh V, Siena S, Henry D, Woll P, Manegold C, et al. Overall survival improvement in patients with lung cancer treated with denosumab versus zoledronic acid: results from a randomised phase 3 study. International Association for the Study of Lung Cancer, 14th World Conference, Amsterdam, Netherlands, 3-7 July 2011.
210. Adami S, Salvagno G, Guarrera G. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985;134:1152-4.
211. Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, et al. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat 2010;124:733-43. http://dx.doi.org/10.1007/ s10549-010-1183-6
212. Saad F. Should patients with prostate cancer without bone metastases receive sodium clodronate? Commentary. Nat Clin Pract Urol 2007;4:584-5. http://dx.doi.org/10.1038/ncpuro0911
213. Kotteas E, Alamara C, Kiagia M, Pantazopoulos K, Boufas A, Provata A, et al. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience. Anticancer Res 2008;28:529-33.